Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional Tembexa® (Brincidofovir) to Support National Preparedness Efforts
Emergent Biosolutions宣佈執行合同期權，價值6740萬美元，以購買額外的Tembexa®（Brincidofovir）來支持國家應急準備工作